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Abstract
Background: Hereditary angioedema (HAE) is a rare but serious disease marked by swelling attacks in the
extremities, face, trunk, airway, or abdominal areas that can be spontaneous or the result of trauma and other
triggers. It can be life-threatening due to the risk of asphyxiation. While there have been major advancements in
our understanding of the immunogenetics of HAE, there are significant gaps in the literature regarding
understanding of the humanistic and economic impact of the disease, particularly in Europe. The purpose of the
HAE Burden of Illness Study-Europe (HAE-BOIS-Europe), the development and methodology of which is described
here, is to better understand the management and impact of HAE from the patient perspective in Europe.
Methods/Design: This is a cross-sectional study in which retrospective data were also collected being conducted in
Denmark, Germany and Spain. The study is open to patients ages 12 and older with a diagnosis of HAE-I or HAE-II.
Data collection includes: (i) a survey on individuals’ health care resource use, direct and indirect medical costs,
impact on work and school, treatment satisfaction, and emotional functioning (via the Hospital Anxiety and
Depression Scale); and (ii) one-on-one interviews to collect detailed descriptive data and patient testimonials on the
impact of HAE on patients’ health-related quality of life.
Discussion: The present manuscript describes the development and plans for implementing a multi-country European
study with the aim of characterizing the humanistic and economic burden of HAE from the patient perspective. This
study will help raise awareness of HAE as a rare but debilitating condition with wide-ranging impacts.
Background
Hereditary angioedema (HAE) is a rare but serious auto-
somal dominant disorder marked by swelling attacks in
the extremities, face, trunk, airways, or abdominal areas
that can be spontaneous or the result of trauma [1]
(Figure 1). Attacks can be serious; the risk of dying from
airway obstruction, if left untreated, has been estimated
at 30 % [2,3]. Attack frequency is described in the litera-
ture as ranging from rarely to once every 3 days [4].
Untreated, patients on average experience attacks every
one to two weeks [5].
The prevalence of HAE is estimated to be approxi-
mately 1 in every 50,000 persons, with no marked
differences among ethnic groups [6,7]. The rarity of the
disease, together with the fact that 6.1–13.7 % of patients
may be asymptomatic or have delayed symptom onset
[7-9], means that, while HAE symptoms often begin in
early childhood and persist throughout patients’ lives,
awareness of the condition is extremely low, and diagno-
sis is frequently delayed. As observed in a Danish study,
the mean delay to diagnosis can be as great as 16 years
[7]. There is therefore an urgent need to raise awareness
of the disease and its appropriate diagnosis and treatment
among clinicians and families who have a hereditary
predisposition to the condition.
Improvements in our understanding of the disease
process have led to the recent availability of an increased
range of treatment options for HAE. Disease manage-
ment takes the form of treatment of acute attacks, short-
term prophylactic treatment for the prevention of attacks
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(for example, before a surgical procedure), and long-term
prophylactic treatment (prevention) to minimize the
frequency and severity of ongoing attacks [5,10,11]. Treat-
ments currently approved in Europe for acute attacks in-
clude plasma derived (pd) C1-inhibitor [human]
concentrate (Berinert, Cetor), pd nano-filtered C1-inhibitor
[human] (Cinryze), recombinant C1-inhibitor (Ruconest/
Rhucin), and use of a bradykinin B2 receptor antagonist
(Firazyr). Long-term prophylaxis (prevention) options have
traditionally involved androgens (such as danazol or stano-
zolol), although their approval status for HAE varies among
European countries. Cinryze is the only agent to have
received European approval for both the treatment and
pre-procedure prevention of angioedema attacks in adults
and adolescents with HAE, as well as for the routine pre-
vention of angioedema attacks in adults and adolescents.
The mechanisms underlying what prompts HAE attacks
to start and resolve are relatively unknown. Moreover, the
severity of symptoms is highly variable both from one pa-
tient to another and within a given patient [5]. The uncer-
tainty surrounding the onset of an attack can cause great
anxiety for patients given that the swelling—especially
when affecting the airways—can be fatal. HAE may, there-
fore, have a substantial emotional impact on the patient as
well as on his or her family. In a cross-sectional survey
using the Hamilton Depression Inventory – Short Form
questionnaire (HDI-SF), 42.5 % of HAE patients had
scores indicative of depressive symptomatology [12]. Such
findings suggest the importance of considering potential
mental health impacts like stress, in addition to traditional
treatment, in the clinical management of these patients in
order to reduce the burden of HAE on daily life.
Some studies, including both interventional and case
studies, have explored the health-related quality of life
(HRQoL) impacts of HAE. Interventional studies have
used general health status measures like the SF-36 and
SF-12, and the Dermatology Life Quality Index (DLQI),
which focuses on dermatological quality of life issues, and
have found them to be associated with improvements in
several quality of life areas, including both physical and
psychological parameters [13-16]. However, authors noted
limitations of the DLQI, as it was originally created for use
in patients with chronic dermatological diseases with
exacerbations such as psoriasis and refers to symptoms
that may not be relevant for HAE. Also, it does not take
acute attacks into consideration and therefore does not
allow to measure patients’ HRQoL both during an attack
and in between attacks.
The SF-36 and SF-12 and general HRQoL measures
are useful for making comparisons across disease areas,
but they may fail to capture specific HRQoL manifesta-
tions of HAE. As Lumry and colleagues (2010) showed,
HAE was associated with detriments in HRQoL across
physical and mental health domains and in each subscale
of both the SF-12 and HDI-SF [12]. However, without
in-depth elaboration from patients, the interpretation of
these impacts, particularly those that are primarily phys-
ical, is limited. Second, while depression was assessed by
way of the HDI-SF, anxiety, arguably an important
emotional marker for any chronic condition marked by
sudden attacks, was not captured in this measure.
Prior and colleagues are developing an international
multi-language HAE-specific HRQoL measure for adults,
the IHAE-QoL [17,18]. The pilot study has been
completed in 12 countries (Argentina, Austria, Brazil,
Canada, Denmark, France, Germany, Hungary, Israel,
Poland, Romania, and Spain) and the psychometric study
is being performed in order to validate this instrument
(T Caballero, personal communication). This disease-
specific questionnaire is expected to give more detailed
and relevant data on HRQoL in HAE patients in the
years ahead. However, this measure is, as of the publish-
ing of the present article, still unavailable.
While there have been advances in our understanding
of the burden of illness in HAE, significant gaps in our
knowledge remain, particularly with regards to the
humanistic and economic burden of the disease
(Figure 2). There is a dearth of data on: the economic
impact of HAE; comparisons of HAE treatment patterns,
patient characteristics, and outcomes in different coun-
tries; the impact of HAE on adolescents; and qualitative
research, including interviews and/or focus group studies
with HAE patients. In addition, utility weights (prefer-
ence values) have not been published for HAE. Such
Figure 1 HAE patient experiencing HAE attacks.
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weights may be used to quality-adjust life expectancy for
use in economic evaluations of medical interventions.
Finally, no-one has yet developed a conceptual model
visually depicting the relationships between HAE disease
symptoms and more distal impacts, such as impact on
career advancement and educational attainment.
There is also a critical need for better epidemiological
data on HAE generally. The data from this study will
help further inform such data. In addition, the findings
likely can be compared with those from other studies, in-
cluding HAE registries, such as the Sweha-Reg [19], the
European Register of HAE [20], and observational stud-
ies such as the HAE nationwide survey conducted in
Denmark [7].
Given the aforementioned gaps in our knowledge of
HAE, the objective of the HAE Burden of Illness Study-
Europe (HAE-BOIS-Europe) is to characterize the hu-
manistic and economic burden of HAE from the patient
perspective. This large-scale, scientifically robust, multi-
country European study evaluates the real-world experi-
ence of HAE patients with respect to resource utilization
and HRQoL burden of HAE in Germany, Denmark, and
Spain. It collects qualitative data in addition to quantita-
tive data to support a conceptual model of the patient-
perceived impacts of HAE on HRQoL, showing the qual-
ity of life and economic burden of HAE both in relation
to acute attacks as well as the long-term experience of
HAE. The present paper describes the development and
plans for implementation of this multi-country European
study, the initial findings of which will be publicly avail-
able in 2012.
Methods
The HAE-BOIS-Europe is a cross-sectional study in
which retrospective data were also collected conducted
in Denmark, Germany and Spain, with participating
patients being recruited from HAE centres of excellence,
as well as HAE patient associations in each country.
The two data collection components include a web- or
paper-based questionnaire and one-on-one telephone
interviews, designed to collect both quantitative and
qualitative data from patients as illustrated in Figure 3.
To be eligible for inclusion in the study, patients must
have a diagnosis of HAE-I or HAE-II (with C-1 inhibitor
deficiency), be aged 12 years or older, have had at least
one attack in the past six months, and demonstrate ad-
equate fluency in the language in which they are taking
the survey/interview. Patients with HAE-III or acquired
angioedema are not eligible for inclusion into the study.
Ethics review and patient confidentiality
Prior to study recruitment, the protocol, including the
questionnaire and interview guide, were translated into
the native language of each target country and submitted
to the ethics review board of each Centre as per the par-
ticular requirements of each Centre. The elements of
country-specific regulations pertaining to consent proce-
dures, disclosure of potential risks and benefits and sub-
ject confidentiality have been strictly observed. All study
subjects are required to read and endorse a consent form
(for participants aged 12–17, parents endorse the con-
sent form and adolescents then endorse an assent form
before data collection).
For the individual telephone interviews, the study coord-
inator screens patients, and those eligible and interested
are scheduled for an anonymous telephone interview to be
conducted by an interviewer trained in qualitative research
by the research company Oxford Outcomes. All inter-
viewers are fluent in the native language of the country in
which the interview is taking place.
Figure 2 Gaps in the literature with regard to the humanistic and economic burden of HAE.
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Recruitment
The principal investigators at the HAE Centres of Excel-
lence in Frankfurt, Germany (Klinikum der Johann Wolf-
gang Goethe-Universität Frankfurt), Odense, Denmark
(Odense Universitetshospital), and Madrid, Spain
(Hospital Universitario La Paz) have contacted poten-
tially eligible patients via mail, email or phone and/or
advertised the study at the respective sites. In addition,
the HAE patient associations in Denmark, Germany, and
Spain have advertised the study on their website and/or
have contacted members in their database. Contact has
been made via phone, mail, or email with individuals
who have noted that they would like to be contacted for
HAE-related studies. The recruitment process has been
designed to minimize selection bias. Specifically, in
Denmark, almost all HAE patients have been invited;
in Germany and Spain, all potentially eligible patients in
the patient organization database, and a random sample
of patients from the HAE Centers of Excellence, were
invited.
Consistent with other burden of illness studies of rare
conditions in Europe [21,22], the target sample size is
150. This sample size is sufficient to identify key impacts
of HAE. The plan is to include equal numbers (n = 50)
from each country, ensuring that each country-specific
sample was generalizable through random sampling. For
the telephone interviews, the target sample size is 30
patients with HAE (10 per country). Previous qualitative
research has found that after twelve interviews, between
88 and 92 % of themes can be identified [23].
The invitation letter includes a username and password
used to access the survey; this allows individuals to
return to the survey and complete it in multiple sittings.
Patients who access the web link are screened online in
the initial questions, and are led automatically to the
consent forms and web survey. Patients without internet
access call the study coordinator for a telephone screen-
ing; if the patient is eligible and interested, the study
coordinator obtains the contact information to send the
paper based consent form and survey. A summary of the
study procedures is illustrated in Figure 4.
Instruments
The questionnaire is comprised of six sections intended
to assess healthcare resource use and indirect costs.
Examples of the data collected in each section are illu-
strated in Figure 5. The last section includes assessment
of current anxiety and depression using the Hospital
Figure 4 Summary of study procedures.
Figure 3 Study data collection components.
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Anxiety and Depression Scale (HADS), a validated 14
item scale to assess anxiety and depression [24]. The
HADS was developed specifically to identify the likeli-
hood of ‘caseness (or confirmed diagnostic condition)’
with respect to anxiety disorders and depression among
patients in non-psychiatric settings [24].
The one-on-one interviews are conducted using a
semi-structured interview guide. The questions are
largely open-ended, allowing the patient to discuss all
the various ways that HAE impacts his/her life,
such as what is it like to live with HAE, how HAE affects
day-to-day activities, and impact of HAE on school
and work advancement. Participants are also asked
socio-demographic questions during the telephone
interviews. Selected questions are the following:
 What is it like to live with HAE?
 Since being diagnosed with HAE, has your life
changed? In what ways?
 What aspect of HAE is the most burdensome?
 When was your last HAE attack?
∘ Can you describe what this was like?
∘ Could you tell that you were about to have an
attack?
∘ How much did your attack affect your activities?
In what way?
 What does it feel like between attacks?
 How does having HAE affect your daily life?
∘ Does it affect your social life?
∘ Does it affect your relationships?
∘ Does it affect your ability to work or attend
school?
∘ Does this differ based on location of the attack?
 Are there any symptoms of HAE other than the
attacks that impact your life in any way?
The surveys were pilot tested in Denmark, Spain, and
Germany with nine participants who met the eligibility
criteria and provided feedback on the survey. The pilot
testers provided valuable feedback such as clarifying
wording in certain questions, but no major changes to
the surveys were required or proposed. In general,
Figure 5 Overview of study questionnaire.
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patients who took the pilot test found the survey under-
standable and highly relevant to their disease.
Analysis
Table 1 summarises the major anticipated analyses from
HAE-BOIS-Europe. Descriptive analyses, including
means, 95 % confidence intervals, and percentages, will
be used to describe the medical resource utilization and
work productivity variables in the survey. The Hospital
Anxiety and Depression Scale (HADS) will be scored as
recommended by the developer [24].
The analyses conducted in the HAE-BOIS-Europe
study will yield such benefits as the potential to:
 Gain a comprehensive understanding of the
humanistic and the direct and indirect resource
impacts of HAE from the European patient
perspective
 Provide feedback to patients and their families on
the patient community experience with HAE
 Help advocate and raise awareness of HAE among
policymakers and the global community
 Help raise awareness of the full impact of HAE
among the clinical community and contribute to
professional education on HAE
This study also will provide an opportunity to explore
different categorizations of HAE severity, for example,
using attack frequency, duration of swelling, worst pain
associated with attack, etc. and their associations with
medical resource utilization and impact on ability to
perform daily activities. Such analyses may help elucidate
how well selected definitions of disease severity differen-
tiate among functional and resource utilization impacts
and may help inform clinical management decisions.
Recent international consensus guidelines on HAE
management, for example, do not provide detail on as-
sessment of disease severity [10].
In addition, the study may provide data that can be used
to estimate health utility (preference) weights for HAE.
Health utilities are weights scaled from 0.0 (death) to 1.0
(full health). Such weights are used in cost-effectiveness
evaluations to quality-adjust life expectancy, thereby produ-
cing quality-adjusted life years (QALYs) for medical inter-
ventions. Although the HAE-BOIS-Europe study does not
directly collect utility data, we plan to estimate utilities for
having an acute HAE attack as well as for chronic disease
(in between attacks) using the survey data. Specifically, to
estimate utilities for an acute attack, we plan to map
response items from the burden of illness survey to corre-
sponding items of the EQ-5D, a widely used utility ques-
tionnaire. These burden of illness items inquire about
worst pain during the most recent attack, the duration that
the attack prevented daily activities, the extent that the
attack affected ability to perform regular activities, and
anxiety about future attacks. We will map the responses to
these items to the respective items within the EQ-5D
and arrive at an estimated utility for an acute attack. The
EQ-5D is a standardised instrument for use as a measure
of health outcome that is applicable to a wide range of
health conditions and is recommended by the UK’s Na-
tional Institute for Health and Clinical Excellence (NICE)
[25]. A similar methodology will be used to estimate util-
ities for chronic HAE (in between attacks).
With respect to the one-on-one interviews, the inter-
view scripts will be evaluated to identify key impacts of
HAE and to provide context for enhancing interpretation
of the survey findings. In qualitative research, there are
no power calculations to determine sample size; rather,
interviews should continue until saturation—that is, the
point at which no new information is being obtained—is
reached. In general, saturation is attained by the 10th or
12th interview. The findings will help substantiate and
refine the conceptual model on the burden of illness of
HAE.
Draft conceptual model
Conceptual models draw on a number of theories and
concepts to help understand a particular problem in a
specific population. Specifically, a conceptual model
diagram shows relationships among a set of concepts
such as disease symptoms, treatment, outcomes, and
patient perceptions [26,27]. Conceptual models integrate
biological and psychological aspects of health outcomes
and can help to better understand the patient experience
with a disease and specific areas that could benefit from
treatment. Figure 6 shows a draft of such a conceptual
model for HAE that illustrates both proximal as well as
long-term impacts of HAE. This model was developed
based on the initial review of the literature; it will be
refined based on data from the current study.
Table 1 Summary of the major anticipated analyses of
data from HAE-BOIS-Europe
Data source Analyses
Survey data Descriptive analyses, eg.• Treatments used• Medical
resource utilization• Impact on work and school
productivity• Reliance on volunteer and paid helpers•
HADS scores and other HRQoL estimates
Potential categorizations of HAE severity (frequency,
pain, duration, etc)
Estimated health utility weights for:• An acute HAE
attack – based on survey responses mapped to the
EQ-5D• Chronic disease – based on HADS scores
mapped to the EQ-5D
Interviews Key concepts important to patients with HAE•
Providing context to survey-derived quantitative
findings• Providing input into the draft conceptual
model of HAE burden of illness
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Discussion and conclusion
As with other rare conditions, knowledge of HAE can be
limited even among medical professionals. There is there-
fore a need to collect and understand data describing the
clinical, economic, and HRQoL impact of the disorder.
While there has been a trend toward trying to better
understand the burden of illness in HAE in recent years,
a number of key gaps in the literature remain that have
prevented a comprehensive understanding of the real-life
experience of patients living with HAE and their families.
A 2010 study by Wilson and colleagues [28] explored
costs associated with HAE in the US and showed a
considerable economic burden to patients, payers, and
society at large. A study by Lumry et al. (2010) discussed
humanistic impacts in the same sample but qualitative
interviews with patients were not conducted [12]. Thus a
study that includes both an economic evaluation and in-
depth qualitative research in Europe would be a useful
addition to the literature.
Our study will build upon the US study [12,28], how-
ever, aspects of it will be more robust. For example, our
study will: include adolescents; include patients recruited
from patient organizations as well as medical centres;
undergo ethics review at clinical sites to ensure data
protection and sound methodology; include individual
qualitative patient interviews; be conducted in parallel in
three countries; and provide data on the humanistic
burden in addition to the economic burden of illness.
Further, it is hoped that the present study will provide a
more comprehensive picture of the overall impact of
HAE in that it will evaluate the impact both during acute
HAE attacks and in-between attacks. The study will also
allow the evaluation of any differences in outcomes for
patients who report that their disease is well-controlled
as opposed to those who consider their disease as poorly
controlled. Ultimately, this study should help to better
understand the impact of HAE from the patient perspec-
tive and may be very valuable in order to increase aware-
ness of the impact of HAE on individuals and the
respective health care systems in which HAE individuals
are treated.
In conclusion, the HAE-BOIS Europe study is as
the first study of its kind in Europe to obtain a com-
prehensive picture of HAE from the patient perspec-
tive. Its findings should help make HAE more visible
in the European and global community, providing
evidence for rational stakeholder discussion and informed
interventions to help improve the lives of patients living
with HAE.
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